Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05575219 · ClinicalTrials.gov registry record · Phase 4
Protocolized Initiation of Clonidine to Prevent Dexmedetomidine Withdrawal
A Phase 4 study of Withdrawal; Therapeutic Substance, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 128
- Enrollment target
- 1
- Study location
NCT05575219 is a Phase 4 study of Withdrawal; Therapeutic Substance that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 128 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05575219, a Phase 4 study of Withdrawal; Therapeutic Substance, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 128 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if the protocolized use of clonidine will reduce dexmedetomidine withdrawal symptoms, reduce PICU length of stay, and reduce costs related to sedation during hospital admission.
Conditions Studied
Interventions
- DRUG Clonidine (without protocolized initiation)
- DRUG Clonidine (protocolized initiation)
Study Locations (1)
Texas
- Children's Memorial Hermann Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2022-10-08 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05575219
The ClinicalTrials.gov registry entry for NCT05575219 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Withdrawal; Therapeutic Substance appearing as the primary indexed condition, and to 2 interventions - of which Clonidine (without protocolized initiation) is the first listed.
NCT05575219 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05575219 about?
NCT05575219 is a clinical study titled "Protocolized Initiation of Clonidine to Prevent Dexmedetomidine Withdrawal". The purpose of this study is to determine if the protocolized use of clonidine will reduce dexmedetomidine withdrawal symptoms, reduce PICU length of stay, and reduce costs related to sedation during hospital admission.
What is the current status of trial NCT05575219?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 128 participants. The study started on 2022-10-08. Estimated completion is 2024-02-15.
What conditions does trial NCT05575219 study?
This clinical trial studies the following conditions: Withdrawal; Therapeutic Substance.
What interventions are being tested in trial NCT05575219?
The interventions under investigation include: Clonidine (without protocolized initiation) (DRUG), Clonidine (protocolized initiation) (DRUG).
Who is sponsoring clinical trial NCT05575219?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05575219 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.